B6.129-Fasl^tm1Lest/Orl

Status	Available to order
EMMA ID	EM:13304
Citation information	RRID:IMSR_EM:13304 Research Resource Identifiers (RRID) are persistent unique ID numbers assigned to help researchers cite key resources (e.g. antibodies, model organisms and software projects) in the biomedical literature to improve transparency and reproducibility in research. See https://www.rrids.org/ for more information.
International strain name	B6.129-Fasl^tm1Lest/Orl
Alternative name	C57BL/6-Faslfl/fl
Strain type	Targeted Mutant Strains : Conditional mutation
Allele/Transgene symbol	Fasl^tm1Lest
Gene/Transgene symbol	Fasl

Information from provider

Provider	Saoussen Karray
Provider affiliation	INSERM
Genetic information	First Fas ligand (Fasl) gene targeted mutation established by S. Karray & M. Levi-Strauss at Institut National de Santé et de Recherche Médicale (INSERM), Paris, France. Fasl floxed allele was designed to have loxP sites flanking Fas ligand gene. Targeting construct was transfected into 129/Sv ES cells and ES clones selected for homologous recombination. ES clones with the targeted allele were injected into C57BL/6 blastocysts.
Phenotypic information	Homozygous: Mice homozygous for floxed allele (Fasl fl/fl) showed no obvious abnormalities. Moreover, the absence of the abnormal CD3+B220+CD4-CD8- T-cell population, typical of gld mice (natural mutant of Fasl gene), indicated a normal function of the floxed allele. Heterozygous: No obvious abnormalities
Breeding history	Chimeras mice were bred with C57BL/6 mice for at least 12 generations.
References	Complete loss of Fas ligand gene causes massive lymphoproliferation and early death, indicating a residual activity of gld allele.;Karray Saoussen, Kress Chantal, Cuvellier Sylvain, Hue-Beauvais Catherine, Damotte Diane, Babinet Charles, Lévi-Strauss Matthieu, ;2004;Journal of immunology (Baltimore, Md. : 1950);172;2118-25; 14764677 Prevention of autoimmunity and control of recall response to exogenous antigen by Fas death receptor ligand expression on T cells.;Mabrouk Imed, Buart Stéphanie, Hasmim Meriem, Michiels Christelle, Connault Elizabeth, Opolon Paule, Chiocchia Gilles, Lévi-Strauss Matthieu, Chouaib Salem, Karray Saoussen, ;2008;Immunity;29;922-33; 19013083
Homozygous fertile	yes
Homozygous viable	yes
Homozygous matings required	no
Immunocompromised	no

Information from EMMA

Archiving centre	CNRS-TAAM – Typing and Archiving of Animal Models, Orléans, France
Animals used for archiving	homozygous C57BL/6 males

Disease and phenotype information

MGI phenotypes (gene matching)

increased leukocyte cell number / MGI
increased neutrophil cell number / MGI
decreased granulocyte number / MGI
enlarged liver / MGI
abnormal hepatocyte morphology / MGI
abnormal salivary gland morphology / MGI
lymphoid hyperplasia / MGI
enlarged spleen / MGI
enlarged lymph nodes / MGI
enlarged thymus / MGI
demyelination / MGI
dermatitis / MGI
increased metastatic potential / MGI
abnormal osteoclast physiology / MGI
anemia / MGI
focal hepatic necrosis / MGI
skin edema / MGI
impaired macrophage phagocytosis / MGI
abnormal humoral immune response / MGI
decreased IgG level / MGI
autoimmune response / MGI
brain inflammation / MGI
eye inflammation / MGI
liver inflammation / MGI
interstitial pneumonia / MGI
neoplasm / MGI
premature death / MGI
abnormal definitive hematopoiesis / MGI
abnormal T cell differentiation / MGI
no abnormal phenotype detected / MGI
abnormal lymph node morphology / MGI
abnormal double-negative T cell morphology / MGI
increased susceptibility to bacterial infection / MGI
increased susceptibility to viral infection / MGI
abnormal T cell physiology / MGI
increased immunoglobulin level / MGI
increased IgG level / MGI
increased IgM level / MGI
increased IgA level / MGI
increased IgE level / MGI
abnormal sperm number / MGI
glomerulonephritis / MGI
decreased circulating alanine transaminase level / MGI
increased urine protein level / MGI
decreased neuron apoptosis / MGI
increased autoantibody level / MGI
abnormal sperm physiology / MGI
increased anti-double stranded DNA antibody level / MGI
increased anti-nuclear antigen antibody level / MGI
increased susceptibility to systemic lupus erythematosus / MGI
increased spleen weight / MGI
increased lymphocyte cell number / MGI
increased T cell number / MGI
decreased B cell number / MGI
abnormal cytotoxic T cell physiology / MGI
decreased cytotoxic T cell cytolysis / MGI
abnormal T cell proliferation / MGI
increased B cell proliferation / MGI
decreased susceptibility to injury / MGI
increased T cell proliferation / MGI
renal/urinary system phenotype / MGI
homeostasis/metabolism phenotype / MGI
cardiovascular system phenotype / MGI
immune system phenotype / MGI
reproductive system phenotype / MGI
vision/eye phenotype / MGI
abnormal eye electrophysiology / MGI
increased apoptosis / MGI
CNS inflammation / MGI
abnormal retinal nerve fiber layer morphology / MGI
decreased retinal ganglion cell number / MGI
increased liver tumor incidence / MGI
abnormal T cell morphology / MGI
abnormal retinal ganglion cell morphology / MGI
retinal ganglion cell degeneration / MGI
increased plasma cell number / MGI
increased germinal center B cell number / MGI
increased IgG1 level / MGI
increased IgG2a level / MGI
increased IgG2b level / MGI
increased circulating tumor necrosis factor level / MGI
abnormal interleukin level / MGI
abnormal thymus cell ratio / MGI
decreased hepatocyte apoptosis / MGI
increased histiocytic sarcoma incidence / MGI
abnormal NK cell physiology / MGI
mortality/aging / MGI
renal cast / MGI
glomerular crescent / MGI
increased lymphoma incidence / MGI
impaired humoral immune response / MGI
increased retinal apoptosis / MGI

Literature references

Complete loss of Fas ligand gene causes massive lymphoproliferation and early death, indicating a residual activity of gld allele.;Karray Saoussen, Kress Chantal, Cuvellier Sylvain, Hue-Beauvais Catherine, Damotte Diane, Babinet Charles, Lévi-Strauss Matthieu, ;2004;Journal of immunology (Baltimore, Md. : 1950);172;2118-25; 14764677
Prevention of autoimmunity and control of recall response to exogenous antigen by Fas death receptor ligand expression on T cells.;Mabrouk Imed, Buart Stéphanie, Hasmim Meriem, Michiels Christelle, Connault Elizabeth, Opolon Paule, Chiocchia Gilles, Lévi-Strauss Matthieu, Chouaib Salem, Karray Saoussen, ;2008;Immunity;29;922-33; 19013083

Information on how we integrate external resources can be found here

Order

Availabilities

Requesting frozen sperm or embryos is generally advisable wherever possible, in order to minimise the shipment of live mice.

Frozen sperm. Delivered in 4 weeks (after paperwork in place). €1740^*
Rederivation of mice from frozen stock, delivery time available upon request . €3880^*

Due to the dynamic nature of our processes strain availability may change at short notice. The local repository manager will advise you in these circumstances.

^* In addition users have to cover all the shipping costs (including the cost for returning dry-shippers, where applicable).

More details on pricing and delivery times

Practical information

Genotyping protocol

Example health report
(Current health report will be provided later)

Material Transfer Agreement (MTA)
For this strain no provider MTA is needed. Distribution is based on the EMMA conditions only.

EMMA conditions
Legally binding conditions for the transfer

Right strain for your research?

The information provided on this page is, to the best of EMMA’s knowledge, based on data supplied by the original provider. End users are responsible for reviewing these details and for validating the strain and its suitability for their experimental use.
Not found what you were looking for? Search here for other strains available from EMMA.

B6.129-Fasltm1Lest/Orl